{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:48:40Z","timestamp":1793821720582,"version":"4.6.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Biohaven Pharmaceuticals, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s12325-022-02386-w","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T10:51:10Z","timestamp":1673952670000},"page":"1141-1152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Observational Analysis of the Costs Associated with Acute Treatment of Breakthrough Migraine Attacks in Medicaid Patients Using Preventive Therapies"],"prefix":"10.1007","volume":"40","author":[{"given":"Linda","family":"Harris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4634-8649","authenticated-orcid":false,"given":"Tom","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"Woolley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"L\u2019Italien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamela","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Coric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Moren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,17]]},"reference":[{"issue":"1","key":"2386_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211.","journal-title":"Cephalalgia"},{"key":"2386_CR2","doi-asserted-by":"crossref","unstructured":"GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954\u201376.","DOI":"10.1016\/S1474-4422(18)30322-3"},{"key":"2386_CR3","doi-asserted-by":"crossref","unstructured":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211\u201359.","DOI":"10.1016\/S0140-6736(17)32154-2"},{"issue":"4","key":"2386_CR4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/head.13281","volume":"58","author":"R Burch","year":"2018","unstructured":"Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache. 2018;58(4):496\u2013505.","journal-title":"Headache"},{"issue":"7","key":"2386_CR5","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021\u201339.","journal-title":"Headache"},{"issue":"4","key":"2386_CR6","first-page":"243","volume":"97","author":"L Mayans","year":"2018","unstructured":"Mayans L, Walling A. Acute migraine headache: treatment strategies. Am Fam Physician. 2018;97(4):243\u201351.","journal-title":"Am Fam Physician"},{"issue":"1","key":"2386_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"The American Headache Society","year":"2019","unstructured":"The American Headache Society. Position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1\u201318.","journal-title":"Headache"},{"issue":"5","key":"2386_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343\u20139.","journal-title":"Neurology"},{"key":"2386_CR9","unstructured":"Lipton RB. Headache horizons: the promise of dual treatment for migraine. Practical Neurology. 2021. https:\/\/practicalneurology.com\/articles\/2021-oct\/headache-horizons-the-promise-of-dual-treatment-for-migraine. Accessed 21 June 2022."},{"issue":"8","key":"2386_CR10","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s40263-021-00834-9","volume":"35","author":"LH Overeem","year":"2021","unstructured":"Overeem LH, Raffaelli B, Mecklenburg J, Kelderman T, Neeb L, Reuter U. Indirect comparison of topiramate and monoclonal antibodies against CGRP or its receptor for the prophylaxis of episodic migraine: a systematic review with meta-analysis. CNS Drugs. 2021;35(8):805\u201320.","journal-title":"CNS Drugs"},{"issue":"10","key":"2386_CR11","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102420941839","volume":"40","author":"HC Diener","year":"2020","unstructured":"Diener HC, Tassorelli C, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia. 2020;40(10):1026\u201344.","journal-title":"Cephalalgia"},{"issue":"1","key":"2386_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12874-019-0664-5","volume":"19","author":"GL Di Tanna","year":"2019","unstructured":"Di Tanna GL, Porter JK, Lipton RB, et al. Migraine day frequency in migraine prevention: longitudinal modelling approaches. BMC Med Res Methodol. 2019;19(1):20.","journal-title":"BMC Med Res Methodol"},{"issue":"8","key":"2386_CR13","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1080\/13696998.2020.1754840","volume":"23","author":"R Mahon","year":"2020","unstructured":"Mahon R, Huels J, Hacking V, et al. Economic evaluations in migraine: systematic literature review and a novel approach. J Med Econ. 2020;23(8):864\u201376.","journal-title":"J Med Econ"},{"issue":"3","key":"2386_CR14","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s41669-018-0105-0","volume":"3","author":"JK Porter","year":"2019","unstructured":"Porter JK, Di Tanna GL, Lipton RB, Sapra S, Villa G. Costs of acute headache medication use and productivity losses among patients with migraine: insights from three randomized controlled trials. Pharmacoecon Open. 2019;3(3):411\u20137.","journal-title":"Pharmacoecon Open"},{"issue":"1","key":"2386_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I, et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020;21(1):32.","journal-title":"J Headache Pain"},{"issue":"9","key":"2386_CR16","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/head.13951","volume":"60","author":"J Robblee","year":"2020","unstructured":"Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ. Real-world patient experience with erenumab for the preventive treatment of migraine. Headache. 2020;60(9):2014\u201325.","journal-title":"Headache"},{"key":"2386_CR17","unstructured":"Medicaid.gov. February 2021 Medicaid & CHIP enrollment data highlights. https:\/\/www.medicaid.gov\/medicaid\/program-information\/medicaid-and-chip-enrollment-data\/report-highlights\/index.html. Accessed 12 Sept 2022."},{"key":"2386_CR18","unstructured":"Benefits.gov. Medicaid Program. https:\/\/www.benefits.gov\/benefit\/606. Accessed 12 Sept 2022."},{"issue":"10","key":"2386_CR19","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1111\/head.13421","volume":"58","author":"SD Silberstein","year":"2018","unstructured":"Silberstein SD, Lee L, Gandhi K, Fitzgerald T, Bell J, Cohen JM. Health care resource utilization and migraine disability along the migraine continuum among patients treated for migraine. Headache. 2018;58(10):1579\u201392.","journal-title":"Headache"},{"key":"2386_CR20","unstructured":"Pennsylvania Department of Human Services. Prior authorization of migraine prevention agents (formerly antimigraine agents, other)\u2014pharmacy services. 2020. https:\/\/www.dhs.pa.gov\/providers\/Pharmacy-Services\/Documents\/Clinical%20Guidelines%20SW%20PDL\/Migraine%20Prevention%20Agents%2001.03.22.pdf. Accessed 12 Sept 2022."},{"key":"2386_CR21","unstructured":"Medi-Cal. Injections: drugs E-H policy\u2014Eptinezumab-jjmr injection (Vyepti\u2122). 2021. https:\/\/files.medi-cal.ca.gov\/pubsdoco\/publications\/masters-mtp\/part2\/injectdruge-h.pdf. Accessed 12 Sept 2022."},{"key":"2386_CR22","unstructured":"American Heart Association. Fact sheet: critical coverage for heart health: medicaid and cardiovascular disease. https:\/\/www.heart.org\/-\/media\/Files\/About-Us\/Policy-Research\/Fact-Sheets\/Access-to-Care\/Medicaid-and-CVD-Fact-Sheet.pdf. Accessed 12 Sept 2022."},{"issue":"6s2","key":"2386_CR23","doi-asserted-by":"publisher","first-page":"S143","DOI":"10.1016\/j.amepre.2017.07.019","volume":"53","author":"JM Chapel","year":"2017","unstructured":"Chapel JM, Ritchey MD, Zhang D, Wang G. Prevalence and medical costs of chronic diseases among adult medicaid beneficiaries. Am J Prev Med. 2017;53(6s2):S143\u201354.","journal-title":"Am J Prev Med"},{"issue":"6","key":"2386_CR24","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","volume":"117","author":"RB D'Agostino Sr","year":"2008","unstructured":"D\u2019Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743\u201353.","journal-title":"Circulation"},{"issue":"1","key":"2386_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s10194-022-01476-y","volume":"23","author":"JL Nguyen","year":"2022","unstructured":"Nguyen JL, Munshi K, Peasah SK, et al. Trends in utilization and costs of migraine medications, 2017\u20132020. J Headache Pain. 2022;23(1):111.","journal-title":"J Headache Pain"},{"issue":"1","key":"2386_CR26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s10194-022-01492-y","volume":"23","author":"S Khanal","year":"2022","unstructured":"Khanal S, Underwood M, Naghdi S, et al. A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine. J Headache Pain. 2022;23(1):122.","journal-title":"J Headache Pain"},{"key":"2386_CR27","unstructured":"Dolan R. Understanding the Medicaid prescription drug rebate program. Kaiser Family Foundation. 2019. https:\/\/www.kff.org\/medicaid\/issue-brief\/understanding-the-medicaid-prescription-drug-rebate-program\/. Accessed 21 June 2022."},{"key":"2386_CR28","unstructured":"Medicaid.gov. State Drug Utilization Data FAQs. 2021. https:\/\/www.medicaid.gov\/medicaid\/prescription-drugs\/state-drug-utilization-data\/state-drug-utilization-data-faq\/index.html. Accessed 21 June 2022."},{"key":"2386_CR29","unstructured":"Gifford K, Winter A, Wiant L, Dolan R, Tian M, Garfield R. How state Medicaid programs are managing prescription drug costs: results from a State Medicaid Pharmacy Survey for state fiscal years 2019 and 2020. Kaiser Family Foundation. 2020. https:\/\/www.kff.org\/report-section\/how-state-medicaid-programs-are-managing-prescription-drug-costs-pharmacy-benefit-administration\/. Accessed 21 June 2022."},{"key":"2386_CR30","unstructured":"Medicaid.gov. State Drug Utilization Data FAQs\u2014what are the data field descriptions for the State Drug Utilization Data (SDUD)? 2021. https:\/\/www.medicaid.gov\/medicaid\/prescription-drugs\/state-drug-utilization-data\/state-drug-utilization-data-faq\/index.html. Accessed 21 June 2022."},{"key":"2386_CR31","unstructured":"United States Food and Drug Administration. National Drug Code Directory. Current through 11\/05\/2020. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ndc\/index.cfm. Accessed 12 Sept 2022."},{"issue":"4","key":"2386_CR32","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(16)00019-3","volume":"15","author":"H Sun","year":"2016","unstructured":"Sun H, Dodick DW, Silberstein S, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(4):382\u201390.","journal-title":"Lancet Neurol"},{"issue":"6","key":"2386_CR33","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425\u201334.","journal-title":"Lancet Neurol"},{"issue":"22","key":"2386_CR34","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123\u201332.","journal-title":"N Engl J Med"},{"key":"2386_CR35","unstructured":"Kaiser Family Foundation. State health facts\u2014share of Medicaid population covered under different delivery systems. 2019. https:\/\/www.kff.org\/medicaid\/state-indicator\/share-of-medicaid-population-covered-under-different-delivery-systems\/?currentTimeframe=0&sortModel=%7B. Accessed 21 June 2022."},{"key":"2386_CR36","unstructured":"Kaiser Family Foundation. State health facts\u2014total monthly Medicaid\/CHIP enrollment and pre-ACA enrollment. 2019. https:\/\/www.kff.org\/health-reform\/state-indicator\/total-monthly-medicaid-and-chip-enrollment\/?currentTimeframe=22&sortModel=%7B. Accessed 21 June 2022."},{"issue":"10","key":"2386_CR37","doi-asserted-by":"publisher","first-page":"5087","DOI":"10.1007\/s12325-021-01781-z","volume":"38","author":"L Harris","year":"2021","unstructured":"Harris L, L\u2019Italien G, O\u2019Connell T, Hasan Z, Hutchinson S, Lucas S. A framework for estimating the eligible patient population for new migraine acute therapies in the United States. Adv Ther. 2021;38(10):5087\u201397.","journal-title":"Adv Ther"},{"issue":"1","key":"2386_CR38","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.1016\/j.jval.2021.11.675","volume":"25","author":"L Harris","year":"2021","unstructured":"Harris L, L\u2019Italien G, Croop R, et al. Estimated migraine patient population in England progressing beyond first-line acute management. Value Health. 2021;25(1):S140.","journal-title":"Value Health"},{"key":"2386_CR39","unstructured":"Institute for Clinical and Economic Review. Acute treatments for migraine\u2014final evidence report. 2020. https:\/\/icer-review.org\/wp-content\/uploads\/2019\/06\/ICER_Acute-Migraine_Final-Evidence-Report_updated_030320.pdf. Accessed 21 June 2022."},{"issue":"2","key":"2386_CR40","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/0333102416636055","volume":"37","author":"M Torres-Ferr\u00fas","year":"2017","unstructured":"Torres-Ferr\u00fas M, Quintana M, Fernandez-Morales J, Alvarez-Sabin J, Pozo-Rosich P. When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month. Cephalalgia. 2017;37(2):104\u201313.","journal-title":"Cephalalgia"},{"issue":"7","key":"2386_CR41","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/13696998.2018.1457533","volume":"21","author":"RB Lipton","year":"2018","unstructured":"Lipton RB, Brennan A, Palmer S, et al. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. J Med Econ. 2018;21(7):666\u201375.","journal-title":"J Med Econ"},{"key":"2386_CR42","unstructured":"RED BOOK Online. IBM Micromedex [database online]. https:\/\/www.micromedexsolutions.com. Accessed 12 Sept 2022."},{"key":"2386_CR43","unstructured":"Institute for Clinical and Economic Review. Calcitonin gene-related peptide (CGRP) Inhibitors as preventive treatments for patients with episodic or chronic migraine: effectiveness and value\u2014final evidence report. 2018. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_Migraine_Final_Evidence_Report_070318-1.pdf. Accessed 12 Sept 2022."},{"issue":"Suppl 4","key":"2386_CR44","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/head.12601","volume":"55","author":"C Cameron","year":"2015","unstructured":"Cameron C, Kelly S, Hsieh SC, et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache. 2015;55(Suppl 4):221\u201335.","journal-title":"Headache"},{"issue":"1","key":"2386_CR45","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12883-019-1420-5","volume":"19","author":"LS Loo","year":"2019","unstructured":"Loo LS, Plato BM, Turner IM, et al. Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN). BMC Neurol. 2019;19(1):191.","journal-title":"BMC Neurol"},{"issue":"19","key":"2386_CR46","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.2019.16711","volume":"322","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887\u201398.","journal-title":"JAMA"},{"key":"2386_CR47","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2147\/JPR.S203650","volume":"13","author":"R Shafqat","year":"2020","unstructured":"Shafqat R, Flores-Montanez Y, Delbono V, Nahas SJ. Updated evaluation of IV dihydroergotamine (DHE) for refractory migraine: patient selection and special considerations. J Pain Res. 2020;13:859\u201364.","journal-title":"J Pain Res"},{"key":"2386_CR48","unstructured":"Nurtec ODT prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212728s006lbl.pdf. Accessed 21 June 2022."},{"key":"2386_CR49","unstructured":"Aimovig prescribing information. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761077s011lbl.pdf. Accessed 21 June 2022."},{"key":"2386_CR50","unstructured":"Ajovy prescribing information. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761089s013lbl.pdf. Accessed 21 June 2022."},{"key":"2386_CR51","unstructured":"Emgality prescrbing information. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761063s004lbl.pdf. Accessed 21 June 2022."},{"key":"2386_CR52","unstructured":"Vyepti prescribing information. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761119s002lbl.pdf. Accessed 21 June 2022."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02386-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02386-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02386-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T21:35:42Z","timestamp":1701725742000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02386-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,17]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["2386"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02386-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,17]]},"assertion":[{"value":"21 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}